Leadership

our executive leadership team

Our team of seasoned industry veterans can anticipate your study challenges and proactively seek solutions.

Executive Leadership Team

Rob King

Chief Executive Officer

Claudia Christian

Chief Commercial Officer

Ghiorghis (George) Belai

Vice President,
Global Strategy

Abraham Van Wyk

Chief Financial Officer

General Management Team

Joy Carson

Global Head,
Clinical Science

Jemee Tegli

Assistant Director,
External Partnerships, Liberia, PREVAIL

Leonard Herbst

Global Head,
Clinical Affairs

Melvin Johnson

Deputy Director,
Clinical Operations,
Liberia, PREVAIL

Sanchia Theron

Global Head,

Medical Affairs

Julia Mulbah Lysander

Deputy Director,
Program, Security

Marié van Wyk

Global Head,
Regulatory Affairs

Christopher Mikaelian

Global Head,
Global Contracts & Procurement

Joy Toro

Global Head,
Global Strategy

Gary Cook

Global Head,
Information Technology

Alan Hampton

Global Head,
Business Finance

Kimberly Malone

Senior Director,
Clinical Operations

Marlie Smit

Senior Director,
Clinical Operations

Craig McNees

Senior Director,
Client Solutions

Fiona Storer

Director,
Clinical Operations

Valentine Veena

Director,

Clinical Operations (Africa)

Gia Malka

Director,
Clinical Operations

Felicia Ricks

Director,

Quality Management Systems and Standards

Karin Banks

Director,
Finance

Linda Duursema

Director, Quality Assurance, Africa Quality Management

about

Global Offices

U.S.A (Headquarters)
359 Blackwell Street, Suite 200, Durham, NC 27701 USA

South Africa
121 Amkor Road, Lyttelton Manor, Centurion, 0157, SOUTH AFRICA

Kenya
Britam Towers, 24th Floor, Hospital Road, Upper Hill KENYA

Liberia
The Cape Hotel, Mamba Point, Monrovia LIBERIA

get in touch

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

Joy Carson

Global Head, Clinical Science

Joy Carson brings more than 30 years of clinical research industry experience to her role as FHI Global Head of Clinical Science. Carson draws on her experience from academia, industry and contract research organizations to support the clinical development of small and large molecules, diagnostics and gene therapies from pre-clinical stages through product launch. She has designed and led studies from early phase and clinical pharmacology through registration and post-marketing in North America, Europe, Latin America, Asia and Africa.

Prior to joining FHI Clinical, Carson served as VP of Clinical Development and VP of Medical Communications at Asklepios Biopharmaceutical, where, in addition to contributing to the clinical development strategy for gene therapy candidates in rare diseases, she established a patient advocacy program to integrate the patient voice into the clinical development process.

Through her career, Carson held multiple positions of increasing responsibility in project management and clinical strategy. She designed and ran the first drug lottery programs for HIV protease inhibitors. Carson led the clinical development of what would become one of the first liquid biopsy assays for cancer detection. She advised global emerging biopharma clients on the development of their oncology assets, with specific experience assisting Asia-Pacific clients to transition their early-phase drug candidates through INDs in North America and Europe. She engaged with regulatory agencies across all phases of drug development and supported global regulatory submissions from IND through market launch.

Carson’s involvement in protocol design across therapeutic indications and phases of development allows her to bring insights into the evolution of study design and methods that support the most direct path to market for new products. Her recruitment and coordination of Clinical and Scientific Advisory Boards has introduced her to global key opinion leaders across clinical indications. Her leadership roles through the years included media relations and government outreach, including the recruitment of a US President and members of the US Congress and Senate in support of a patient advocacy fundraiser. Carson’s passion is coordinating clinicians, regulators, government, industry and patient advocates to advance global health initiatives.

Carson holds a BA in neuropsychology from Boston University and an MBA from the D’Amore-McKim School of Business High Technology Program at Northeastern University.